Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
View graph of relations

Expertises

Multicolor Flow cytometry; Genetic engineering; Lentiviral transduction; mRNA transfection; Cell cultures; PCR; Sequencing; Magnetic bead and Flow based Cell sorting; Western Blot; Calcium influx, Transwell Migration, Proliferation and Cytotoxicity assays; In vivo mouse models; In vivo Imaging;

Main research areas

Cancer Immune Therapy; Exercise and Cancer;

Current research

Genetic engineering of T cells for adoptive cell therapy of cancer.

Adoptive cell therapy (ACT) represents a promising treatment modality for the treatment of disseminated cancer. Using in vitro expanded T cells from biopsy material, this strategy has led to clinical responses in 50% and potential cures in 20% of metastatic patients. Recruitment of transferred lymphocytes to the tumor site is a crucial measure for successful ACT, however, to this end, quite few T cells eventually reach the tumor site upon administration. Chemokine/receptor interaction plays an important role in T cell trafficking towards lymph nodes and inflamed tissues. However, many tumors express chemokines that divert homing of anti-tumor T cells and rather promotes homing of cells with suppressive action, thus promoting tumor progression and metastasis. By engineering T cells to express appropriate homing receptors we attempt to exploit the chemokine expression by tumors therapeutically. In the present pre-clinical study we will arm T cells with chemokine receptors CXCR2, among others by viral transduction, aiming at improving the homing of adoptively transferred T cells and augment the anti-tumor efficacy of ACT.

Potential conflicts of interest

None

ID: 36833121